Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 2
1976 1
1977 1
1978 2
1979 4
1980 7
1981 5
1982 4
1983 4
1984 8
1985 9
1986 15
1987 11
1988 15
1989 16
1990 20
1991 25
1992 17
1993 26
1994 32
1995 35
1996 42
1997 32
1998 35
1999 34
2000 57
2001 76
2002 58
2003 61
2004 70
2005 78
2006 73
2007 43
2008 51
2009 35
2010 30
2011 20
2012 25
2013 33
2014 30
2015 22
2016 34
2017 31
2018 24
2019 16
2020 20
2021 22
2022 20
2023 16
2024 23
2025 17
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,301 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Self-administered subcutaneous medroxyprogesterone acetate for improving contraceptive outcomes: a systematic review and meta-analysis.
Nabhan A, Elshafeey F, Mehrain LM, Kabra R, Elshabrawy A. Nabhan A, et al. BMC Womens Health. 2021 Oct 9;21(1):359. doi: 10.1186/s12905-021-01495-y. BMC Womens Health. 2021. PMID: 34627229 Free PMC article.
BACKGROUND: Subcutaneous depot medroxyprogesterone acetate is an easy-to-use injectable contraceptive. A trained person can administer it, including women through self-injection. ...CONCLUSIONS: Self-injection of subcutaneous depot medroxyprogesterone acetate probab …
BACKGROUND: Subcutaneous depot medroxyprogesterone acetate is an easy-to-use injectable contraceptive. A trained person can administe …
Depot medroxyprogesterone acetate: implications for weight status and bone mineral density in the adolescent female.
Bonny AE, Harkness LS, Cromer BA. Bonny AE, et al. Adolesc Med Clin. 2005 Oct;16(3):569-84. doi: 10.1016/j.admecli.2005.05.006. Adolesc Med Clin. 2005. PMID: 16183540
Depot medroxyprogesterone acetate (DMPA) is an effective and easy-to-use contraceptive method for adolescents. ...
Depot medroxyprogesterone acetate (DMPA) is an effective and easy-to-use contraceptive method for adolescents. ...
Efficacy and safety of medroxyprogesterone acetate on noninvasive ventilation -treated exacerbated COPD patients: a double-blind randomized clinical trial.
Jelodar MG, Malek-Ahmadi M, Sahebnasagh A, Mohammadi F, Saghafi F. Jelodar MG, et al. BMC Pulm Med. 2025 Mar 10;25(1):107. doi: 10.1186/s12890-024-03462-3. BMC Pulm Med. 2025. PMID: 40065288 Free PMC article. Clinical Trial.
Noninvasive ventilation (NIV) and respiratory stimulant drugs are used to treat this condition. Medroxyprogesterone acetate (MPA) can cross the blood-brain barrier and cause breathing stimulation and hyperventilation. ...
Noninvasive ventilation (NIV) and respiratory stimulant drugs are used to treat this condition. Medroxyprogesterone acetate (MPA) can …
Comprehensive meta-analysis of the effects of oral medroxyprogesterone acetate plus conjugated equine oestrogens on the lipid profile in women: Insights from randomized controlled trials.
Zhang YL, Xie L, Wu FL, Ding X, Hernández-Wolters B, Găman MA, Kord-Varkaneh H. Zhang YL, et al. Eur J Clin Invest. 2024 Aug;54(8):e14211. doi: 10.1111/eci.14211. Epub 2024 May 10. Eur J Clin Invest. 2024. PMID: 38726889
At present, data on the effect of the administration of medroxyprogesterone acetate plus conjugated equine oestrogens (MPACEE) on the lipid profile in females are uncertain, as the investigations conducted so far have produced conflicting results. ...
At present, data on the effect of the administration of medroxyprogesterone acetate plus conjugated equine oestrogens (MPACEE) on the …
Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.
Kaunitz AM, Arias R, McClung M. Kaunitz AM, et al. Contraception. 2008 Feb;77(2):67-76. doi: 10.1016/j.contraception.2007.10.005. Contraception. 2008. PMID: 18226668
BACKGROUND: While depot medroxyprogesterone acetate (DMPA) is a highly effective contraceptive used by millions of women, its use is associated with bone mineral density (BMD) loss, raising concerns about long-term risk of osteoporosis and/or fractures. ...
BACKGROUND: While depot medroxyprogesterone acetate (DMPA) is a highly effective contraceptive used by millions of women, its use is …
Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis.
Yuk JS, Song JY, Lee JH, Park WI, Ahn HS, Kim HJ. Yuk JS, et al. Ann Surg Oncol. 2017 May;24(5):1322-1329. doi: 10.1245/s10434-016-5699-9. Epub 2016 Nov 28. Ann Surg Oncol. 2017. PMID: 27896507 Review.
BACKGROUND: This study aimed to compare the levonorgestrel-releasing intrauterine system (LNG-IUS) with oral cyclic medroxyprogesterone acetate (MPA) in endometrial hyperplasia therapy using randomized controlled trials (RCTs). ...
BACKGROUND: This study aimed to compare the levonorgestrel-releasing intrauterine system (LNG-IUS) with oral cyclic medroxyprogesterone …
Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials.
Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thomson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski-Wende J; WHI Investigators. Manson JE, et al. JAMA. 2017 Sep 12;318(10):927-938. doi: 10.1001/jama.2017.11217. JAMA. 2017. PMID: 28898378 Free PMC article. Clinical Trial.
INTERVENTIONS: Conjugated equine estrogens (CEE, 0.625 mg/d) plus medroxyprogesterone acetate (MPA, 2.5 mg/d) (n = 8506) vs placebo (n = 8102) for 5.6 years (median) or CEE alone (n = 5310) vs placebo (n = 5429) for 7.2 years (median). ...
INTERVENTIONS: Conjugated equine estrogens (CEE, 0.625 mg/d) plus medroxyprogesterone acetate (MPA, 2.5 mg/d) (n = 8506) vs placebo ( …
A meta-analysis of the efficacy of progestin-primed ovarian stimulation with medroxyprogesterone acetate in ovulation induction in poor ovarian responders.
Cai R, Zheng B, Lin Q, Deng J, Zeng X, Lin W, Shi D. Cai R, et al. J Gynecol Obstet Hum Reprod. 2021 Sep;50(7):102049. doi: 10.1016/j.jogoh.2020.102049. Epub 2020 Dec 30. J Gynecol Obstet Hum Reprod. 2021. PMID: 33387677 Free article.
METHOD: A literature search of PubMed, Medline, EBSCO, Cochrane Library, Vip.com, CNKI, and the Wanfang database was conducted to find case-control studies of PPOS with medroxyprogesterone acetate and other traditional stimulation regimens for ovulation induction in patien …
METHOD: A literature search of PubMed, Medline, EBSCO, Cochrane Library, Vip.com, CNKI, and the Wanfang database was conducted to find case- …
Medroxyprogesterone Acetate versus Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surge in hyper-responder women undergoing controlled ovarian stimulation for IVF/ICSI Cycles.
Tandulwadkar S, Gupta S, Singh A, Mishra S, Singhania S. Tandulwadkar S, et al. JBRA Assist Reprod. 2023 Mar 30;27(1):15-19. doi: 10.5935/1518-0557.20220006. JBRA Assist Reprod. 2023. PMID: 35621299 Free PMC article. Clinical Trial.
OBJECTIVE: To compare the effect of Medroxyprogesterone acetate versus Gonadotropin releasing hormone antagonist for the prevention of premature luteinizing hormone (LH) surge in infertile hyper-responder women undergoing controlled ovarian stimulation for in vitro fertili …
OBJECTIVE: To compare the effect of Medroxyprogesterone acetate versus Gonadotropin releasing hormone antagonist for the prevention o …
Medroxyprogesterone acetate and homozygous sickle-cell disease.
De Ceulaer K, Gruber C, Hayes R, Serjeant GR. De Ceulaer K, et al. Lancet. 1982 Jul 31;2(8292):229-31. doi: 10.1016/s0140-6736(82)90320-8. Lancet. 1982. PMID: 6178915 Clinical Trial.
The haematological and clinical effects of medroxyprogesterone acetate in homozygous sickle-cell (SS) disease were assessed in a 2-year controlled crossover trial completed by 23 patients. ...Painful crises were significantly less frequent during the medroxyprogesterone …
The haematological and clinical effects of medroxyprogesterone acetate in homozygous sickle-cell (SS) disease were assessed in a 2-ye …
1,301 results